Performance of Hepatitis C Virus (HCV) Core Antigen Assay in the Diagnosis of Recently Acquired HCV Infection among High-Risk Populations

Microbiol Spectr. 2022 Jun 29;10(3):e0034522. doi: 10.1128/spectrum.00345-22. Epub 2022 May 17.

Abstract

How the hepatitis C virus (HCV) core antigen (HCVcAg) assay performs in detecting recently acquired HCV infection among people living with HIV (PLWH) and HIV-negative men who have sex with men (MSM) is rarely assessed in the Asia-Pacific region. High-risk participants, including PLWH with sexually transmitted infections (STIs), HCV clearance by antivirals or spontaneously, or elevated aminotransferases, HIV-negative MSM with STIs or on HIV preexposure prophylaxis, and low-risk PLWH were enrolled. Blood samples were subjected to 3-stage pooled-plasma HCV RNA testing every 3 to 6 months until detection of HCV viremia or completion of the 1-year follow-up. The samples at enrollment and all of the archived samples preceding the detection of HCV RNA during follow-up were tested for HCVcAg. During June 2019 and February 2021, 1,639 blood samples from 744 high-risk and 727 low-risk PLWH and 86 HIV-negative participants were tested for both HCV RNA and HCVcAg. Of 62 samples positive for HCV RNA, 54 (87.1%) were positive for HCVcAg. Of 1,577 samples negative for HCV RNA, 1,568 (99.4%) were negative for HCVcAg. The mean HCV RNA load of the 8 individual samples positive for HCV RNA but negative for HCVcAg was 3.2 (range, 2.5 to 3.9) log10 IU/mL, and that of the remaining 54 samples with concordant results was 6.2 (range, 1.3 to 8.5) log10 IU/mL. The positive predictive value (PPV) and negative predictive value (NPV) of HCVcAg were 85.7% and 99.5%, respectively. In at-risk populations, HCVcAg has a high specificity and NPV but lower sensitivity and PPV, particularly in individuals with low HCV RNA loads. IMPORTANCE The HCV core antigen assay has a high specificity of 99.4% and negative predictive value of 99.5% but a lower sensitivity of 87.1% and positive predictive value of 85.7% in the diagnosis of recently acquired HCV infection in high-risk populations. Our findings are informative for many countries confronted with limited resources to timely identify acute HCV infections and provide effective direct-acting antivirals to halt onward transmission.

Keywords: HCV core antigen assay; HCV viremia; men who have sex with men; negative predictive value; pooled-plasma HCV RNA testing; positive predictive value; preexposure prophylaxis; sensitivity; sexually transmitted infection; specificity; viral hepatitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • HIV Infections* / diagnosis
  • HIV Infections* / drug therapy
  • Hepacivirus / genetics
  • Hepatitis C Antigens / genetics
  • Hepatitis C Antigens / therapeutic use
  • Hepatitis C* / drug therapy
  • Hepatitis C, Chronic* / diagnosis
  • Homosexuality, Male
  • Humans
  • Male
  • RNA, Viral / genetics
  • Sensitivity and Specificity
  • Sexual and Gender Minorities*
  • Viral Core Proteins / genetics
  • Viral Core Proteins / therapeutic use

Substances

  • Antiviral Agents
  • Hepatitis C Antigens
  • RNA, Viral
  • Viral Core Proteins